Amicus Says No NDA for Fabry Disease Treatment This Year

Drug Industry Daily
A A
The FDA has asked Amicus Therapeutics to integrate data from two Phase 3 studies of its Fabry disease treatment migalastat, pushing back its NDA filing until early 2016.

To View This Article:

Login

Subscribe To Drug Industry Daily